| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | IL2RG; P64; CIDX; IMD4; SCIDX; IL-2RG; SCIDX1 |
| Entrez GeneID | 3561 |
| clone | 4A8F2 |
| WB Predicted band size | 42.3kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD132 (AA: extra 23-262) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于MSH2抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**：*Immunohistochemistry versus Microsatellite Instability Testing in Screening for Lynch Syndrome*
**作者**：Lindor NM, et al.
**摘要**：该研究比较了免疫组化(使用MSH2等错配修复蛋白抗体)与微卫星不稳定性检测在林奇综合征筛查中的效能，发现MSH2抗体在识别DNA错配修复缺陷患者中具有高特异性，可作为遗传性结直肠癌筛查的重要工具。
2. **文献名称**：*Performance of Antibodies in the Detection of Mismatch Repair Proteins in Endometrial Cancer*
**作者**：Shia J, et al.
**摘要**：研究评估了不同克隆号MSH2抗体在子宫内膜癌组织中的敏感性和特异性，提出优化抗体选择可提高错配修复蛋白缺失的检测准确性，对林奇综合征诊断和预后评估具有重要意义。
3. **文献名称**：*Automated Immunohistochemical Screening for Lynch Syndrome*
**作者**：Buchanan DD, et al.
**摘要**：该文献探讨了自动化免疫组化技术结合MSH2抗体在大规模人群筛查林奇综合征中的应用，证明其高效性和成本效益，能够快速识别患者并指导基因检测。
---
以上文献聚焦于MSH2抗体在癌症诊断、遗传筛查及技术优化中的关键作用，为相关研究和临床实践提供了参考依据。
The MSH2 antibody is a crucial tool in studying the DNA mismatch repair (MMR) system, which ensures genomic stability by correcting replication errors. The MSH2 protein, encoded by the *MSH2* gene, forms heterodimers (e.g., with MSH6) to recognize and initiate repair of mismatched DNA bases. Defects in MSH2 are strongly linked to Lynch syndrome, a hereditary condition predisposing individuals to colorectal, endometrial, and other cancers. MSH2 dysfunction leads to microsatellite instability (MSI), a hallmark of MMR deficiency.
In clinical diagnostics, MSH2 antibodies are used in immunohistochemistry (IHC) to assess protein expression in tumor tissues. Loss of MSH2 staining, often alongside other MMR proteins (MLH1. PMS2. MSH6), helps identify Lynch syndrome-associated cancers or sporadic tumors with MMR deficiency. This guides genetic testing, patient management, and immunotherapy decisions, as MSI-high tumors may respond better to immune checkpoint inhibitors.
Researchers also employ MSH2 antibodies in Western blotting, immunofluorescence, and functional studies to explore MMR mechanisms, gene interactions, and therapeutic targets. Commercially available antibodies vary in specificity and applications, requiring validation via controls like MSH2-deficient cell lines. Overall, MSH2 antibodies bridge molecular research and clinical practice, enhancing precision oncology and hereditary cancer risk assessment.
×
